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Differentiation therapy: a promising 
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Abstract 
Poor differentiation is an important hallmark of cancer cells, and differentiation therapy holds great promise for cancer 
treatment. The restoration of IkB kinase α (IKKα) leads to the differentiation of nasopharyngeal carcinoma cells with 
reduced tumorigenicity. The findings by Yan et al. validate the polycomb protein enhancer of zeste homologue 2 
(EZH2) as a target for intervention.
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Traditional chemotherapy or radiotherapy generally 
involves killing tumor cells [1, 2]. However, cancer cells 
may instead be coaxed into becoming normal cells by 
differentiation therapy, which aims to reactivate endog-
enous differentiation programs in cancer cells to resume 
the maturation process and eliminate tumor pheno-
types (Fig.  1). Generally, differentiation agents tend to 
have less toxicity than conventional cancer treatments. 
A prototype differentiation therapy is all-trans-reti-
noic acid (ATRA), which induces complete remission 
in patients with acute promyelocytic leukemia (APL). 
ATRA induces terminal cell differentiation by disrupt-
ing the promyelocytic leukemia/retinoic acid receptor α 
(PML/RARα) fusion protein that arrests the maturation 
of myeloid cells at the promyelocytic stage [3]. Subse-
quently, emerging studies have focused on elucidating 
the mechanisms of action of differentiation therapy in 
cancers, particularly in solid tumors. In a paper pub-
lished on Nature Communications, Yan et al. [4] demon-
strated that restoring IkB kinase α (IKKα) expression led 
to cellular differentiation in nasopharyngeal carcinoma 
(NPC) (Fig. 2).
NPC is a distinct type of head and neck cancer, and 
the undifferentiated type (WHO III) is most prevalent 
(accounting for more than 97% of cases in South China) 
[5]. The reason for the differentiation block is unclear. 
This unique characteristic provides an excellent model 
for exploring the possibility of differentiation therapy 
in NPC. To identify the key molecules that are essen-
tial for NPC cell differentiation, Yan et al. [4] compared 
three paired RNA libraries from NPC tumors and adja-
cent non-tumorous tissues, validated their findings by 
real-time polymerase chain reaction (PCR) and West-
ern blotting assays, and determined that IKKα down-
regulation is involved in the undifferentiated status of 
NPC. This conclusion was also evidenced by the func-
tional analysis, which showed that restoring IKKα in 
poorly differentiated NPC cell lines (including CNE2, 
HONE1, and SUNE1) induced differentiation in  vitro 
and decreased tumorigenicity in vivo. IKKα overexpres-
sion led to both morphologic and molecular changes in 
cells that were comparable to well differentiated NP69 
and CNE1 cells [4]. Additionally, Yan et al. [4] performed 
colony formation and nude mouse xenograft assays to 
reveal the significant suppression of cell proliferation 
and tumor growth in CNE2-IKKα cells. These findings 
suggest that IKKα plays a crucial role in NPC differen-
tiation. This function of IKKα is consistent with the 
result reported by previous studies [6–9] that deleting 
IKKα resulted in a hyperproliferative and undifferenti-
ated epidermis. Moreover, reintroducing IKKα induces 
terminal differentiation and inhibits hyperproliferation 
in IKKα−/− keratinocytes. Although there is clear evi-
dence that decreased IKKα expression is associated with 
high-grade disease and poor differentiation in human 
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squamous cell carcinoma (SCC) [10, 11], the underly-
ing molecular mechanisms for IKKα repression have not 
been completely elucidated.
Furthermore, through luciferase reporter and chro-
matin immunoprecipitation (CHIP) assays, Yan et al. [4] 
demonstrated that IKKα was epigenetically silenced by 
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Fig. 1 Diagram of differentiation therapy. Compared with traditional cancer treatments, such as surgery, chemotherapy, and radiotherapy that 
aim to kill tumor cells, differentiation therapy has opened a new door for the treatment of malignant tumors. Differentiation therapy is based on 
the concept that a neoplasm is a differentiation disorder or a dedifferentiation disease. In response to the induction of differentiation, tumor cells 
can revert to normal or nearly normal cells, thereby altering their malignant phenotype and ultimately alleviating the tumor burden or curing the 












Fig. 2 Restoring IkB kinase α (IKKα) promotes nasopharyngeal carcinoma differentiation. In undifferentiated NPC cells, IKKα is epigenetically sup-
pressed by enhancer of zeste homologue 2 (EZH2) (left). After ATRA treatment, IKKα is restored, and the tumor cells differentiate towards normal 
cells (right). EED, embryonic ectoderm development; SUZ12, suppressor of zeste 12
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an enhancer of zeste homologue 2 (EZH2)-dependent 
mechanism. Moreover, immunohistochemistry analysis 
of multiple primary NPC specimens demonstrated that a 
significant majority of undifferentiated NPC tissues had 
high EZH2 levels and low IKKα expression, indicating 
that the phenomenon described for the intensely studied 
cell line is not isolated.
Importantly, Yan et  al. [4] used a classical differen-
tiation reagent, ATRA, to restore IKKα expression and 
induce the differentiation of poorly differentiated NPC 
cells. They used a 3-dimentional (3D) cell culture model 
and showed that after ATRA treatment, the disordered 
tumor cell mass reorganized into polarized structures 
compatible with clinical non-cancerous nasopharyngeal 
specimens. Certainly, it will be interesting to determine 
the mechanisms by which ATRA reduces the expres-
sion of EZH2 and abrogates EZH2-mediated epigenetic 
repression.
The significance of the study [4] lies not only in its elu-
cidation of IKKα function in NPC differentiation but also 
in the demonstration of the mechanism for IKKα repres-
sion in NPC. Recently, another interesting study reported 
that restoring the function of the tumor suppressor the 
adenomatous polyposis coli (APC) causes complete 
tumor regression with normal differentiation and rees-
tablishes stem cell function in mouse intestinal tumors 
induced by APC inhibition [12]. Together, these findings 
enhance our confidence in differentiation therapy and its 
high translational value in the clinic.
However, many challenges remain for cancer differ-
entiation therapy, particularly in solid tumors. First, 
the molecular mechanisms responsible for differentia-
tion blocks may vary among different tumor types and 
patients, even for tumors of equivalent histological class 
and grade. Second, for the most part, cancer cells cannot 
completely revert to normal cells with relevant function-
ality. Third, although many reagents have demonstrated 
the ability to induce differentiation in preclinical models, 
few such reagents can be applied in the clinic.
There is evidence that epigenetic regulation plays a cru-
cial role in cell differentiation and embryonic develop-
ment, as well as in the self-renewal of cancer stem cells 
[13–15]. Based on the structural and mechanistic com-
plexity of solid tumor differentiation, which is generally 
regulated by a group of genes, exploring the molecular 
mechanisms of epigenetic networks may provide new 
insights for the treatment of solid tumors with differen-
tiation therapy.
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